Lung cancer is the leading cause of cancer death worldwide with Small Cell Lung Cancer (SCLC), an aggressive form with a typical survival rate of 10-12 months, accounting for roughly 14% of all lung cancers. The primary chemotherapy treatment regimen for SCLC is etoposide plus a platinum-based drug such as cisplatin or carboplatin. Although patients initially respond well to this treatment, tumors often develop resistance to this drug protocol. Poor prognostic factors for this type of lung cancer coupled with the fact that the chemotherapy regimen has not changed substantially in 40 years highlight the urgent need to develop new therapeutic approaches to treating SCLC.
Read this case study to learn how Dr. Trudy Oliver and colleagues at the Huntsman Cancer Research Center in Salt Lake City, Utah (USA) used a Genetically Engineered Mouse Model (GEMM) and microCT imaging using the Quantum GX2 system to study and quantify tumor growth, progression, and evaluate treatment approaches in MYC-driven SCLC tumors.